In short
Clinical trials are investigating Vafidemstat in people with schizophrenia. The main goal is to see whether it can improve negative symptoms and cognitive impairment, and to compare it with placebo in adult patients. This article focuses on the trial design, who may take part, and what outcomes are being measured.
Key points
- One clinical trial is studying Vafidemstat in adults with schizophrenia. The study is a Phase 2 interventional trial and is authorised, with 239 planned participants. It compares Vafidemstat with placebo to see whether it improves negative symptoms and cognitive impairment. The main outcome is the change in the PANSS Factor Score for Negative Symptoms from baseline to week 24. The trial is focused on symptom improvement in adult patients with schizophrenia.
Trial overview
The available trial data describe one interventional study of Vafidemstat in schizophrenia. The study is titled the EVOLUTION study and is designed to evaluate the efficacy of Vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia.
This trial is in Phase 2 and has a status of Authorised. The planned enrollment is 239 participants.
Who can participate
The study targets adult patients with schizophrenia. The trial summary says it is meant to assess the effect of Vafidemstat on negative symptoms of schizophrenia in adult patients.
The source data do not provide more detailed entry rules, such as age limits beyond adulthood, symptom severity thresholds, or other medical requirements.
What is being measured
The main outcome is the change in the PANSS Factor Score for Negative Symptoms from baseline to week 24. PANSS is a symptom rating scale used in schizophrenia research, and this part of the score focuses on negative symptoms such as low motivation, less speech, and reduced emotional expression.
“Baseline” means the starting point before treatment effects are measured, and “week 24” means 24 weeks after the study begins. This tells researchers whether the treatment group changes more than the placebo group over time.
Study design and treatment groups
The trial compares Vafidemstat with placebo, which is a look-alike capsule that contains no drug substance. The placebo capsules are described as Swedish orange colored size 3 capsules that look identical to the Vafidemstat capsules.
The intervention is given by oral use, meaning it is taken by mouth. The study is therefore designed to test whether the active treatment leads to better symptom improvement than placebo in a fair comparison.
Why this trial matters
Schizophrenia can include symptoms that are difficult to treat, especially negative symptoms and thinking problems. This trial is important because it focuses on those harder-to-treat areas rather than only on general symptom control.
Because the study is in Phase 2, it is part of the early testing stage that helps show whether a treatment may be useful for larger future studies. The results will help researchers understand if Vafidemstat deserves further study for schizophrenia.